Used in pharmaceutical research as a potent and selective inhibitor of the phosphodiesterase 10A (PDE10A) enzyme. This compound shows promise in the development of treatments for neurological and psychiatric disorders, particularly schizophrenia and Huntington’s disease, due to its ability to modulate signaling pathways in the brain involved in cognition, motivation, and motor control. Its sulfonyl and piperazine oxide moieties contribute to enhanced blood-brain barrier penetration and metabolic stability, making it a valuable scaffold in central nervous system drug discovery. Preclinical studies indicate it has favorable pharmacokinetic properties and low off-target activity, supporting its use as a lead compound in neuropharmacology.